Clinical trials investigating the blockade of IL-17A have been conducted in RA patients, demonstrating modest efficacy compared to its effects in psoriasis, psoriatic arthritis, and spondylarthritis (50). The gene discussed is IL17A; the disease is rheumatoid arthritis.